DUBLIN--(BUSINESS WIRE)--The "Injection Pen Market by Type (Disposable and Reusable Pens), Therapy (Diabetes (Insulin, Glucagon-Like Peptide-1), Growth Hormone Therapy, Osteoporosis, Fertility), End User (Homecare and Hospitals), and Region - Global Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.
The global injection pen market is projected to reach US$41.38 Billion by 2022, from US$30.97 Billion in 2017, at a CAGR of 6% during the forecast period.
The market is segmented on the basis of type, therapy, end user, and region. Based on type, the market is segmented into disposable and reusable injection pens. The disposable injection pens segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the benefits disposable pens offer, such as portability, ease of use, and low possibility of infection.
Based on therapy, the global injection pen market is segmented into diabetes, growth hormone therapy, osteoporosis, fertility, and other therapies (such as multiple sclerosis, obesity, cardiovascular diseases, rheumatoid arthritis, and migraine). The diabetes segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the large diabetic population across the globe and the favorable reimbursement scenario for diabetes treatments in developed countries.
Based on end user, the global market is categorized into homecare and hospital & clinics. The homecare segment is expected to register the highest CAGR during the forecast period due to the growing demand for self-administration drug delivery devices and the growing prevalence of chronic diseases.
The global injection pens market is dominated by Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France). These players adopted growth strategies such as product launches, mergers & acquisitions, and expansions to maintain and enhance their position in the market.
- Growing Prevalence of Chronic Diseases
- Increasing Number of Regulatory Approvals
- Favorable Reimbursement and Government Support
- Preference for Alternative Drug Delivery Modes
- Poor Reimbursement Scenario in Developing Countries
- Patent Expiry of Biologics to Drive the Demand for Biosimilars
- Needle-Stick Injuries & Misuse of Injection Pen
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Injection Pen Market, by Type
7 Injection Pen Market, by Therapy
8 Injection Pen Market, by End User
9 Injection Pen Market, by Region
10 Competitive Landscape
11 Company Profiles
- Becton, Dickinson and Company (BD)
- ELI Lilly and Company
- F.Hoffman-La Roche
- Novo Nordisk
- Owen Mumford
For more information about this report visit https://www.researchandmarkets.com/research/fwbclh/global_injection?w=4